ASSESSMENT OF FEASIBILITY OF DYSLIPIDEMIA CLINICS AND IMPLEMENTATION ATHEROSCLEROSIS PROJECT IN KAZAKHSTAN
Introduction. Established in 2021, the Lipid Clinic Network of Kazakhstan is dedicated to creating a global framework for consistent standards in diagnosing, managing, and treating lipid disorders, guided by the European Society of Cardiology and European Atherosclerosis Society (further - ESC/EAS) Guidelines on dyslipidaemia management.
The aim is to evaluate pillars for LCN in Kazakhstan and assess the feasibility of dyslipidemia clinics and implementation atherosclerosis project in Kazakhstan.
Materials and methods. This is a cross-sectional survey with 8 questions to explore the organization of a lipid clinic network in Kazakhstan. 28 clinics took part and respondents were anonymous. The questionnaire was based on EAS LCN evaluation.
Results. 54 % of dyslipidemia clinics are located in outpatient department and 11% of clinics are located as a sub-department within a cardiology department or similar in the hospital. 71% of clinics (20) show connections to hospital departments including diabetes, endocrinology and rare disease units. The staff composition of LCN Kazakhstan is: physicians - 26, nurses - 20, geneticist expert in dyslipidemias’ - 1, dietitian – 4, nutritionist - 0.
A majority of clinics (53.60%) are situated in outpatient departments, highlighting a prevalent reliance on outpatient care for lipid-related services. The physician and nurse staffing levels align with LCN-EAS standards, the lack of nutritionists, geneticists, and dietitians represents a significant gap in the multidisciplinary care model advocated by the EAS. Capacity to provide therapeutic education on lifestyle changes, cardiovascular disease (CVD) prevention, and adherence to treatment is present in 16 clinics.
Conclusion. Some criteria of LCN Kazakhstan are aligned with EAS LCN requirements in terms of data management, location, facility and the, management of the interaction with the patients. However, composition of staff, clinical trial management and connection within the health service infrastructure and patient referral need to be enhanced.
Makhabbat Bekbossynova1, https://orcid.org/0000-0003-2834-617X
Tatyana Ivanova-Razumova1, https://orcid.org/0000-0002-6471-1587
Aknur Kali1, https://orcid.org/0000-0003-3971-1689
Sadyk Khamitov1, https://orcid.org/0000-0001-6296-0507
Gulnur Daniyarova1, https://orcid.org/ 0000-0001-5876-7528
Kamila Akzholova2, https://orcid.org/0009-0000-2527-8947
1. Alieva A. S., Tokgözoğlu L., Ray K. K., Catapano A. L. Lipid Clinics Network. Rationale and design of the EAS global project. Atherosclerosis Supplements. 2020. No. 42. P. e6-e8. DOI: 10.1016/j.atherosclerosissup.2021.01.002
2. Apple S.J., Clark R., Daich J., Gonzalez M.L., Ostfeld R.J., Toth P.P., Bittner V., Martin S.S., Rana J.S., Nasir K., Shapiro M.D., Virani S.S., Slipczuk L. Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models. Reviews in Cardiovascular Medicine. 2023. Vol. 24, No. 12. P. 350. DOI: 10.31083/j.rcm2412350
3. Catapano A.L., Daccord M., Damato E., et al. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis. 2022. Vol. 349. P. 136–143.
4. Catapano A.L., Tokgözoğlu L., Banach M., Gazzotti M., Olmastroni E., Casula M., Ray K.K. Lipid Clinics Network Group. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. Atherosclerosis. 2023. No. 370. P. 5-11. DOI: 10.1016/j.atherosclerosis.2023.02.007
5. Duarte Lau F., Giugliano R.P. Lipoprotein(a) and its significance in cardiovascular disease: a review. JAMA Cardiology. 2022. Vol. 7, No. 7. P. 760–769.
6. Eaton C.B., Galliher J.M., McBride P.E., Bonham A.J., Kappus J.A., Hickner J. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. Journal of the American Board of Family Medicine. 2006. Vol. 19, No. 1. P. 46-53. DOI: 10.3122/jabfm.19.1.46
7. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001. Vol. 357. P. 995–1001. DOI: 10.1016/S0140-6736(00)04235-5
8. Frank L.J., Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Bäck M., Benetos A., Biffi A., Boavida J. M., Capodanno D., Cosyns B., Crawford C., Davos C. H., Desormais I., et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. European Heart Journal. 2021. Vol. 42, No. 34. P. 3227–3337. URL: https://doi.org/10.1093/eurheartj/ehab484
9. Institute for Health Metrics and Evaluation. Kazakhstan. URL: https://www.healthdata.org/research-analysis/health-by-location/profiles/kazakhstan
10. International Atherosclerosis Society. Harmonized Clinical Guidelines on the Prevention of Atherosclerotic Cardiovascular Disease.
11. Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., McKenney J.M., Grundy S.M., Gill E.A., Wild R.A., Wilson D.P., Brown W.V. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. Journal of Clinical Lipidology. 2014. Vol. 8, No. 5. P. 473-88. DOI: 10.1016/j.jacl.2014.07.007
12. JBS 2: Joint British Societies guidelines on the prevention of cardiovascular disease in clinical practice. Heart. 2005. Vol. 91. P. 1–52.
13. Koskinas K.C., Catapano A.L., Baigent C., Tokgozoglu L., Mach F. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology. 2022. Vol. 28, No. 18. P. 2030-2037. DOI: 10.1093/eurjpc/zwaa156
14. Kotseva K., Investigators E. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovascular Diagnosis and Therapy. 2017. Vol. 7. P. 633–639. DOI: 10.21037/cdt.2017.04.06
15. Kronenberg F. Lipoprotein(a). Handbook of Experimental Pharmacology. 2022. No. 270. P. 201–232.
16. Martin S.S., Niles J.K., Kaufman H.W., Awan Z., Elgaddar O., Choi R., Ahn S., Verma R., Nagarajan M., Don-Wauchope A., Castelo M.H. C. G., Hirose C.K., James D., Truman D., et al. Lipid distributions in the Global Diagnostics Network across five continents. European Heart Journal. 2023. Vol. 44, No. 25. P. 2305–2318. DOI: 10.1093/eurheartj/ehad371
17. McEvoy J.W., Jennings C., Kotseva K., De Backer G., De Bacquer D., Erlund I., et al. INTERASPIRE: an international survey of coronary patients; their cardiometabolic, renal and biomarker status; and the quality of preventive care delivered in all WHO regions: in partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology. Current Cardiology Reports. 2021. Vol. 23. P. 136. DOI: 10.1007/s11886-021-01568-2
18. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997. Vol. 349. P. 1498–1504.
19. Ray K.K., Molemans B., Schoonen W. M., Giovas P., Bray S., Kiru G., Murphy J., Banach M., De Servi S., Gaita D., Gouni-Berthold I., et al. DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2021. Vol. 28, No. 11. P. 1279-1289. DOI: 10.1093/eurjpc/zwaa047
20. Wierzbicki A.S., Viljoen A., Viljoen S., Martin S., Crook M.A., Reynolds T.M. Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. International Journal of Clinical Practice. 2018. Vol. 72, No. 9. Article e13242. DOI: 10.1111/ijcp.13242
Количество просмотров: 763
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Bekbossynova M., Ivanova-Razumova T., Kali A., Khamitov S., Daniyarova G., Akzholova K. Assessment of Feasibility of Dyslipidemia Clinics and Implementation Atherosclerosis Project in Kazakhstan // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (4), pp. 46-53. doi 10.34689/SH.2024.26.4.006 Бекбосынова М., Иванова-Разумова Т., Кали А., Хамитов С., ДанияроваПохожие публикации:
ВЗАИМОСВЯЗЬ МЕЖДУ ИНДЕКСОМ МАССЫ ТЕЛА И МИНЕРАЛЬНОЙ ПЛОТНОСТЬЮ КОСТИ У ЛИЦ СРЕДНЕГО И ПОЖИЛОГО ВОЗРАСТА
КЛИНИКО-МОРФОЛОГИЧЕСКАЯ И МОРФОМЕТРИЧЕСКАЯ ОЦЕНКА ГРАНУЛЕМАТОЗНОГО ВОСПАЛЕНИЯ ПРИ САРКОИДОЗЕ И ТУБЕРКУЛЕЗЕ ЛЕГКИХ
DRUG-INDUCED LIVER INJURY IN HIV-INFECTED PATIENTS WITH ACTIVE TUBERCULOSIS: COMPARATIVE LABORATORY CHARACTERIZATION
RESULTS OF THE IMPLEMENTATION OF THE DISEASE MANAGEMENT PROGRAM ON CHRONIC HEART FAILURE IN THE REPUBLIC OF KAZAKHSTAN
КОМОРБИДНОСТЬ ПРИ ОСТЕОАРТРИТЕ